statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ('Biodexa'), an acquisition-focused...

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and...

Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biodexa Pharmaceuticals stock is up alongside heavy trading of BDRX after announcing positive news from a brain cancer treatment...

Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?

Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulinTopline data from Phase 2a program expected by year-endSafety profile established in more than 700...

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Biodexa Pharmaceuticals PLC( Biodexa or the Company ) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall...

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Acciones al alza
Biodexa Pharmaceuticals (NASDAQ:BDRX) se anotaron un alza del 14,48% para establecerse en los 1,66 d lares durante la sesi n del after-market del lunes.
China Pharma Holding...

12 acciones de salud en movimiento en la subasta de cierre del 12/02/2024

LADENBURG THALM/SH SH assumed coverage on shares of Biodexa Pharmaceuticals (NASDAQ:BDRX  Free Report) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The...

Biodexa Pharmaceuticals (NASDAQ:BDRX) Now Covered by Analysts at LADENBURG THALM/SH SH

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Biodexa Pharmaceuticals initiated with bullish view at Ladenburg, here's why

Biodexa Pharmaceuticals reports 12 month survival in MAGIC-G1 study of MTX110

Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa...

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Volume	640,129.00
52-Wk High	$20.80
52-Wk Low	$0.67

BDRX Biodexa Pharmaceuticals Plc

About

Feed

News

Sentiment

Fundamentals